Skip to content
‹ Back to IndustriesSciences

There Aren’t That Many Women in AI Fields, Both in Reality and in Film. What Needs to Change?

Around the world, women make up less than a quarter of the AI workforce. This data, shared by the World Economic Forum (WEF), is indicative of a bias that starts in childhood. According to the WEF, reasons like societal and cultural norms can lead to fewer women taking up STEM education. Experts believe that the…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · · AvengersBechdel TestEx MachinaGender Pay Gap
Share

Key takeaways

01

Around the world, women make up less than a quarter of the AI workforce.

02

This data, shared by the World Economic Forum (WEF), is indicative of a bias that starts in childhood.

03

According to the WEF, reasons like societal and cultural norms can lead to fewer women taking up STEM education.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Around the world, women make up less than a quarter of the AI workforce. This data, shared by the World Economic Forum (WEF), is indicative of a bias that starts in childhood. According to the WEF, reasons like societal and cultural norms can lead to fewer women taking up STEM education. Experts believe that the number of women in AI will only increase when equal opportunities are created for women.

Life imitates art and art imitates life, right? The notion applies to women’s representation in the data science field, too; the WEF’s unfortunate statistic is present even in media content. A study, conducted by Cambridge University researchers, found that barely 8% of AI professionals depicted in popular movies between 1920 and 2020 were women. As many as 1,400 films on AI were reviewed as part of the study, out of which 142 influential films were finally analyzed. A total of 116 AI professionals were identified, of which just nine were female. Prominent movies that were analyzed included Ex Machina, released in 2014, and those from the Avengers franchise.

Dr. Natalie’s Thoughts:

Dr. Natalie Morse, a senior data scientist at Torqata Data and Analytics, discussed why universal childcare and formalized federal parental leave policies could go a long way in changing the current statistics on women in AI and other STEM fields.

“It’s important that we have women represented in film. It is, but it’s more important that we actually create spaces where women can be successful in AI, in tech, in all fields. So, I have been the only female on an all-men tech team where we did R&D focused on AI. It was a Fortune 500 company. It was awesome. The main qualification for being in that room was having your PhD in Computer Science. Same for these films, right? All these tech geniuses, they’ve got their PhDs because you don’t just wake up and become an AI genius. In the US, we graduate about 3,500 PhDs in this space every year, and only 30% are female. So about 850 women each year even have the potential to become these AI leaders and geniuses. The number’s gone up about 6% in the last five years. But it’s still not 50-50 or anywhere close.

So, why are less females going into this space? Let me tell you a story. So I’ve got friends that are married. They’re doctors, they have children. Doctor number one works full-time, doctor number two works part-time. Doctor number one is has even said, “I would actually really like you not to work because it would make my life so much easier.” Guess which one is male and which one is female? Yeah, I think you know, and this story plays out again and again over every kitchen counter in the US, right? Either explicitly or implicitly.

So, why would women go through all this hoopla to get this big degree that’s hard, that’s a PhD, if in five years, they’re expected to become a caretaker anyway? So, that is the bigger problem that tech is up against. We’re asking tech to solve a problem that is bigger than tech, right? It is a cultural problem in the US, right? Tech, politics, finance, medicine, all male-dominated fields and all things that we’re trying to solve, but we’re not actually solving the issue. So, I would love to see more women in film. I would really love to see policies that actually make it okay for women to succeed in industries. That means maybe pay parental leave, maybe childcare for children under five, expanded elder care. All of these things need to exist for women to be successful in AI or any field.”

Rhonda’s Thoughts:

Rhonda Dibachi, CEO of HeyScottie, an AI-enabled and cloud-based service for finishing services, gives her take on STEM numbers in the last 5 years and in her lifetime and where to look for inspiration for needed change.

“I think the stigma has lessened. I think it’s easier for women to be accepted and be attracted to science careers and STEM careers in general. If you take a look at the U.S. Census Bureau statistics in 1970, only 8% of STEM workforce were women. In 2019, that number had risen to 27%, so that’s good. Even though it’s 50 years, it’s within my lifetime and I’ve seen it. So, I like the direction, I like the way it’s going. If you see some young woman who is still having that stigma keeping her from her full potential, I would suggest that she look to role models, and I would suggest that she’d go to Hollywood to see some role models of strong, smart STEM-smart women, because there’s tons of them now, and there didn’t used to be when I was growing up.”

Article by Aarushi Maheshwari & Sonya Young.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz's AAV2 gene therapy for retinitis pigmentosa, through IND-enabling work and a planned Phase 1/2 trial. CLZ002 targets retinal repair, not mutations. Because the disease is linked to more than 90 genes, one manufacturing process could end up serving a broad patient group.

  • 01Retinitis pigmentosa has more than 90 causal genes; CLZ002 aims at a shared retinal repair pathway, so a single AAV2 manufacturing process would serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab hiring budgets for 2027 carry a net outlook of just +2, down from +10, while consumables sit at +30 and raw materials at +31. Labs are paying for supplies and planning capital purchases further ahead. New positions face the toughest scrutiny.

  • 01Labs heading into 2027 expect their reagent budgets to grow and their headcount budgets to stall: consumables carry a net outlook of +30, hiring just +2.
  • 02Lab Manager’s read: if consumables spending stays flat, the lab is probably buying less—because respondents reported rising costs across many supply items, from reagents to shipping.
  • 03Hiring gets treated as a recurring cost, not a one-time purchase; one published example estimates ~$46,000/year for a graduate student and $80,000–$100,000 for a postdoc (with fringe) at one institution. Lab Manager recommends justifying new roles with throughput, turnaround and risk—while separating price from volume in supply-line requests.

Nov 13, 2026

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra BioPharma Solutions opened Building H, a $250 million-plus addition to its Bloomington, Indiana campus, featuring two syringe lines and a vial line with lyophilizers. The CDMO plans to expand from 11 to 18 filling lines by 2027. Extra sites reduce supply risk only when products are qualified at both locations.

  • 01Simtra's network is set to grow from 11 to 18 filling lines across Indiana and Germany by 2027, a published capacity timeline sponsors can plan tech transfers against.
  • 02A second fill site cuts supply risk only after a product has been validated there; for biologics that means process validation, comparability work and regulatory filings first.
  • 03Programs whose real exposure sits in concentrated starting-material supply gain little from added fill-finish redundancy, however well the new lines are built.

Nov 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512